Literature DB >> 27268726

Oncology outcomes in Retroperitoneal sarcomas: Prognostic factors in a Retrospective Cohort study.

Dorian Yarih Garcia-Ortega1, Oscar Villa-Zepeda1, Héctor Martinez-Said1, Mario Cuellar-Hübbe1, Kuauhyama Luna-Ortiz2.   

Abstract

INTRODUCTION: Retroperitoneal sarcomas are a rare group of malignant soft tissue tumors with a generally poor prognosis. The aim of the study was to define the demographic characteristics and prognostic factors for patients with retroperitoneal sarcomas (RPS) in a Tertiary Referral Center at Mexico.
METHODS: A retrospective study of patients with RPS treated from January 2005 to December 2012 at the National Cancer Institute at Mexico. Patient, tumor and treatment variables were analyzed including use of adjuvant therapy and survival status. Survival and local recurrence curves were estimated using the Kaplan-Meier method.
RESULTS: Ninety-five patients with a mean age of 47 years with retroperitoneal sarcoma were included. Median follow-up was 25 months (range 1-108 months). The average tumor size was 23.7 cm. Histology, 58 (61.1%) were liposarcoma, 14 (14.7%), leiomyosarcomas and 23 (24.2%) were from other histologies. In 64 (67.4%) patients were high-grade malignancies. The median survival was 51 months for patients with complete resection, 25.1 months for those with incomplete resection, and 4.4 months for those with unresectable tumors. Complete resection (p = 0.0001), and liposarcoma (p = 0.03) were prognostic factors for overall survival.
CONCLUSION: In this study of patients with retroperitoneal, complete resection and liposarcoma histology are prognostic factors related to the disease-free and overall survival. Patients approached with curative intent should undergo aggressive attempts at complete surgical resection.
Copyright © 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Complete resection; Liposarcoma; Prognostic factors; Recurrence; Retroperitoneal sarcoma; Survival

Mesh:

Year:  2016        PMID: 27268726     DOI: 10.1016/j.ijsu.2016.06.001

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  3 in total

1.  Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma.

Authors:  Eun Byeol Jo; Doopyo Hong; Young Sang Lee; Hyunjoo Lee; Jae Berm Park; Sung Joo Kim
Journal:  Transl Oncol       Date:  2018-11-14       Impact factor: 4.243

2.  Predictors of Disease-Free and Overall Survival in Retroperitoneal Sarcomas: A Modern 16-Year Multi-Institutional Study from the United States Sarcoma Collaboration (USSC).

Authors:  Patrick B Schwartz; Kara Vande Walle; Emily R Winslow; Cecilia G Ethun; Thuy B Tran; George Poultsides; Jennifer Tseng; Kevin Roggin; Valerie Grignol; John Harrison Howard; Bradley A Krasnick; Ryan C Fields; Harveshp Mogal; Callisia N Clarke; Rebecca Senehi; Konstantinos Votanopoulos; Kenneth Cardona; Daniel E Abbott
Journal:  Sarcoma       Date:  2019-06-02

3.  Multiple well-differentiated retroperitoneal liposarcomas with different patterns of appearance on computed tomography: A case report.

Authors:  Tian-Hao Xie; Xiang-Xiang Ren; Yan Fu; Si-Ning Ha; Li-Tao Liu; Xiao-Shi Jin
Journal:  World J Clin Cases       Date:  2021-03-06       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.